In recent years, the use of GLP-1 receptor agonists, such as semaglutide, has gained attention for their potential benefits in treating polycystic ovary syndrome (PCOS), a hormonal disorder affecting millions of women. Grace Hamilton, 27, who struggled with symptoms of PCOS for over a decade, reported significant improvements after participating in a clinical trial for a GLP-1 drug in 2024. Following ten months of treatment, she experienced weight loss, hair regrowth, and enhanced mental well-being.
PCOS is often underdiagnosed and characterized by symptoms including irregular menstrual cycles, excess hair growth, and insulin resistance. Current treatments, such as birth control and lifestyle changes, have limited efficacy, prompting health experts to explore GLP-1s as a potential alternative. Dr. Melanie Cree, a pediatric endocrinologist, has been researching the impact of GLP-1s on PCOS, noting that even modest weight loss can improve insulin sensitivity and alleviate symptoms.
Although early results from clinical trials suggest GLP-1s may help some women with PCOS, responses vary. Insurance coverage remains a significant barrier for many patients seeking these treatments, as most plans only cover GLP-1s for approved uses like diabetes management. The average monthly cost of these medications can exceed $1,000 without insurance.
While anecdotal evidence points to benefits beyond weight loss, including improved menstrual regularity, further research is necessary to establish the effectiveness and safety of GLP-1s for PCOS more conclusively. Experts emphasize the need for larger, more comprehensive studies to clarify the potential of these drugs in addressing various PCOS symptoms and to develop standardized treatment protocols.